Skip to content
Trusted Vision

Giving Pluripotent Cells in Utero to Infants with Spina Bifida Boosts Life Outcomes, Trial Finds

An innovative research effort has revealed that administering stem cells to developing infants affected by spina bifida while undergoing fetal surgery may represent a "important advancement" in managing prenatal disorders.

Trial Details and Safety

The US-based trial involved six developing infants with a severe neural tube defect. Medical teams placed placenta-derived mesenchymal stem cells directly onto the developing neural column as part of the surgical correction.

Significantly, the cell therapy proved to be secure. Researchers confirmed that the therapy did not induce cancerous growths, disrupt the healing process, or prevent the reversal of associated brain abnormalities.

Promising Outcomes

Magnetic resonance imaging performed on the newborns indicated a successful correction of brainstem displacement in each of the babies. This brain structure normalization is closely linked to enhanced physical outcomes.

"If it makes more children able to walk who previously could not, it could establish itself as their standard of care," noted the study director. "The results are extremely promising and open the door to lots of potential innovative interventions."

Long-Term Prospects and Optimism

Commentators reviewing the findings have suggested that subsequent studies of these apparent benefits could signal a "new era" in fetal surgery. The possibility of ameliorating neural deficits present before birth is considered a transformative goal.

Notably important would be better management of urogenital and gastrointestinal outcomes, which are common challenges for those diagnosed with this defect.

Looking Ahead

Despite this being a first-in-human effort was small in scale, its safety demonstration and positive signals create a solid basis for larger, more comprehensive studies. The combination of regenerative medicine with current in-utero repair procedures presents significant potential for changing life trajectories for babies yet to be born with myelomeningocele.

About the author

Rhonda Bird

Aria Chen is a tech journalist and AI researcher with over a decade of experience covering cutting-edge innovations and their societal impacts.

Trusted Vision

Type to search articles.